Lovastatin extended release: a review of its use in the management of hypercholesterolaemia (Q35091923)

6 August 2017

1 reference

title

Lovastatin extended release: a review of its use in the management of hypercholesterolaemia (English)

1 reference

6 August 2017

0 references

1

Monique P Curran

1 reference

6 August 2017

Karen L Goa

2

1 reference

6 August 2017

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

63

1 reference

6 August 2017

7

1 reference

6 August 2017

685-699

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363070-00007

6 August 2017

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia

1 reference

12 December 2020

Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors

1 reference

12 December 2020

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.

1 reference

12 December 2020

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

1 reference

12 December 2020

Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia

1 reference

12 December 2020

Drug treatment of lipid disorders

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide

1 reference

12 December 2020

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

1 reference

12 December 2020

A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin

1 reference

12 December 2020

The liver and lovastatin

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation

1 reference

12 December 2020

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

12 December 2020

Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure

1 reference

12 December 2020

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial

1 reference

12 December 2020

Physiological disposition of HMG-CoA-reductase inhibitors

1 reference

12 December 2020

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

12 December 2020

Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

The physiological disposition of lovastatin

1 reference

12 December 2020

Changes in population cholesterol levels and coronary heart disease deaths in seven countries

1 reference

12 December 2020

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

12 December 2020

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

1 reference

12 December 2020

Management of hypercholesterolemia

1 reference

12 December 2020

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

1 reference

12 December 2020

Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells

1 reference

12 December 2020

Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans

1 reference

12 December 2020

Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein

1 reference

12 December 2020

Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy

1 reference

12 December 2020

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins.

1 reference

12 December 2020

Plasma cortisol and testosterone in hypercholesterolaemia treated with clofibrate and lovastatin

1 reference

12 December 2020

The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study

1 reference

12 December 2020

Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide.

1 reference

12 December 2020

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

12 December 2020

10.2165/00003495-200363070-00007

Identifiers

DOI

1 reference

PubMed ID

12656649

Dimensions Publication ID

6 August 2017

0 references

1 reference

PubMed ID

12656649